Rhesus disease, also known as hemolytic disease of the fetus and newborn, occurs when maternal antibodies attack fetal red blood cells due to Rh incompatibility. This condition typically arises when an Rh-negative mother carries an Rh-positive baby and her immune system becomes sensitized.
Modern antenatal care and postpartum prophylaxis have dramatically reduced severe cases, but understanding risk factors, testing, and treatment options remains essential for clinicians and pregnant individuals.
| Aspect | Key Detail | Clinical Relevance | Current Practice |
|---|---|---|---|
| Cause | Rh(D) antigen incompatibility | IgG anti-D antibodies cross placenta | Preventable with Rh immunoglobulin |
| Risk Window | Delivery, miscarriage, invasive procedures | Sensitization may occur in first pregnancy | Routine antenatal anti-D prophylaxis in many regions |
| Screening | Maternal Rh type and antibody screen | Identifies at-risk pregnancies early | Integrated into first-trimester blood tests |
| Management | Monitoring, intrauterine transfusion, phototherapy | Reduces anemia, hydrops, and neonatal complications | Specialized fetal medicine centers for severe cases |
Pathophysiology of Rhesus Disease
Rhesus disease is driven by an immune response in which an Rh-negative mother produces anti-D antibodies after exposure to Rh-positive fetal blood. During a first sensitizing event, usually delivery, fetal cells enter maternal circulation. Her immune system recognizes the Rh(D) antigen as foreign and generates memory B cells.
In subsequent pregnancies with an Rh-positive fetus, these memory antibodies rapidly cross the placenta and bind fetal red blood cells, causing hemolysis. Unchecked hemolysis can lead to fetal anemia, high-output heart failure, hydrops fetalis, and severe neonatal complications without timely intervention.
Diagnosis and Screening Protocols
Antenatal screening for Rh status and irregular antibodies is standard in most developed health systems. The initial blood type and antibody screen identify whether a pregnant person is Rh-negative and whether anti-D or other clinically significant antibodies are present.
For an Rh-negative, antibody-negative pregnant person, antenatal anti-D immunoglobulin is typically offered around 28 weeks. After delivery, if the baby is Rh-positive, an additional dose is administered within 72 hours to prevent sensitization in future pregnancies.
Monitoring and Treatment Options
Antenatal Surveillance
Once sensitization is confirmed, detailed ultrasound and Doppler assessment of the fetal middle cerebral artery peak systolic velocity help detect anemia. Regular monitoring allows clinicians to time interventions, such as intrauterine transfusion, before severe anemia develops.
Postnatal and Neonatal Care
Newborns at risk may receive intensive phototherapy and, in more severe cases, exchange transfusion to remove circulating antibodies and bilirubin. Close follow-up of bilirubin levels and anemia ensures timely treatment and reduces the risk of long-term neurologic injury from kernicterus.
Prevention Strategies
Primary prevention focuses on preventing alloimmunization in the first place. Routine antenatal anti-D prophylaxis, careful management of fetomaternal hemorrhage, and administration of anti-D after potentially sensitizing events are central to modern programs.
In settings with limited resources, prioritizing Rh typing and targeted postpartum prophylaxis can still reduce the incidence of severe disease. Public health messaging about the importance of early and consistent antenatal care further supports prevention efforts.
Key Takeaways on Rhesus Disease Management
- Confirm Rh type and antibody status early in pregnancy
- Offer antenatal anti-D prophylaxis to eligible Rh-negative individuals
- Monitor antibody levels and fetal well-being with ultrasound and Doppler
- Use intrauterine transfusion for severe fetal anemia when indicated
- Provide postpartum anti-D to prevent sensitization after delivery of an Rh-positive baby
- Ensure neonatal follow-up for bilirubin and anemia after birth
- Coordinate care between obstetric, pediatric, and transfusion services
FAQ
Reader questions
Can rhesus disease affect a first pregnancy?
Yes, although severe disease is less common in the first pregnancy, sensitization can occur during delivery, miscarriage, or invasive procedures, placing the first baby at risk.
What happens if an Rh-negative person receives Rh-positive blood?
Exposure can trigger antibody formation, leading to future pregnancy complications if the person becomes pregnant with an Rh-positive fetus.
How is rhesus disease diagnosed before birth?
Through maternal antibody screening combined with fetal ultrasound and Doppler studies, clinicians can detect anemia and plan timely interventions.
Is a father’s Rh status relevant when planning a family?
Yes, knowing the father’s Rh type helps estimate risk, but the mother’s antibody status and prophylaxis timing remain the primary focus of management.